Opinion|Videos|May 8, 2024
Perspectives on Long-Standing and Novel Treatments for Dry Eye
Richard Adler, MD, FACS, offers key takeaways from a Case-Based Roundtable discussion that focused on the diagnosis and management of dry eye disease.
Advertisement
Advertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Their conversation covers a holistic, cross-specialty approach to ocular surface disease and the unmet need driving a new model of dry eye care in Ireland.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
Dry eye cases rise with heavy screen use and younger patients; learn modern workups spotlighting MGD, etiology-driven treatments, and collaborative care reshaping outcomes.
The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
AAO 2026: Optogenetic gene therapy heads to phase 2 trial in geographic atrophy
2
AAO 2026: BRUNELLO 1-year results for remigromig in DME
3
AAO 2026: MCO-010 sustains vision gains in RP through 4 years
4
Real-world VOYAGER data on faricimab in nAMD, DME, RVO at EURETINA 2026
5